MP35-11 LUTS, ED, AND QOL IMPROVE UNDER LONG-TERM TESTOSTERONE THERAPY IN OBESE MEN WITH FUNCTIONAL HYPOGONADISM

Abstract

You have accessJournal of UrologyCME1 May 2022MP35-11 LUTS, ED, AND QOL IMPROVE UNDER LONG-TERM TESTOSTERONE THERAPY IN OBESE MEN WITH FUNCTIONAL HYPOGONADISM Ahmad Haider, Karim Sultan Haider, Gheorghe Doros, and Abdulmaged Traish Ahmad HaiderAhmad Haider More articles by this author , Karim Sultan HaiderKarim Sultan Haider More articles by this author , Gheorghe DorosGheorghe Doros More articles by this author , and Abdulmaged TraishAbdulmaged Traish More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002589.11AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) in elderly men are closely associated with quality of life (QoL). We aimed to assess long-term effects of testosterone therapy (TTh) in obese hypogonadal men in a registry study. METHODS: Of 476 obese men with functional hypogonadism, 281 men chose TTh by means of testosterone undecanoate (TU) injections 1000 mg/12 weeks following an initial 6-week interval (T-group). 195 men opted against TTh and served as controls (CTRL). 12-year data are presented. Changes over time between groups were compared and adjusted for age, weight, waist circumference, fasting glucose, blood pressure, lipids and quality of life to account for baseline differences between the groups. RESULTS: Mean age at baseline: 59.9±5.5 years (T-group) and 62.9±5.0 (CTRL) (p <0.0001). Mean (median) follow-up: T-group 9.4±3.0 (11), CTRL 8.9±3.0 (10) years. Alpha-blockers were used at baseline by 53.7% in the T-group and 56.4% in CTRL (p=0.3963), PDE5 inhibitors by 23.1% in the T-group and 26.2% in CTRL (p=0.4501). IPSS (baseline: 7.9±3.4) decreased by 5.8±0.2 (p <0.0001) in the T-group in year 12. In CTRL, IPSS (baseline: 5.1±1.8) increased by 4.2±0.3 (p <0.0001). Estimated adjusted difference between groups: −9.3 [95% CI: −10.7; −9.3] (p <0.0001). Residual bladder volume (RBV) in the T-group (baseline: 61.1±22.8) decreased by 48.8±1.6 mL (p <0.0001) in year 12. In CTRL, RBV (baseline: 53.7±16.0) increased by 39.1±2.3 mL (p <0.0001). Estimated adjusted difference between groups: −87.3 mL [95% CI: −93.5; −81.1] (p <0.0001). IIEF-EF in the T-group increased from 17.5±5.9 (mild to moderate) by 11.1±0.3 to 29.2±1.1 (no ED) in year 12. In CTRL, IIEF-EF decreased from 18.9±3.9 (mild to moderate) by 14.4±0.4 to 7.7±1.1 (severe). Estimated adjusted difference between groups: 25.5 (95% CI: 24.5; 26.5) (p <0.0001 for all). QoL, assessed by the Aging Males’ Symptoms scale (AMS), improved from 53.7±9.5 (severe symptoms) by 31.1 points in the T-group to 16.9 (no symptoms) and worsened from 40.0±5.7 (moderate symptoms) by 21.8 points to 69.8 (severe symptoms) in CTRL. CONCLUSIONS: In obese men with functional hypogonadism, long-term TTh improves LUTS and ED sustainably over 12 years. This may have contributed to improvements in QoL. In the untreated control group, LUTS, ED, and QoL deteriorated. Source of Funding: Data entry and statistical analysis was compensated by Bayer AG © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e591 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Ahmad Haider More articles by this author Karim Sultan Haider More articles by this author Gheorghe Doros More articles by this author Abdulmaged Traish More articles by this author Expand All Advertisement PDF DownloadLoading ...